AUPO721997A0 - Anticancer compounds - Google Patents

Anticancer compounds

Info

Publication number
AUPO721997A0
AUPO721997A0 AUPO7219A AUPO721997A AUPO721997A0 AU PO721997 A0 AUPO721997 A0 AU PO721997A0 AU PO7219 A AUPO7219 A AU PO7219A AU PO721997 A AUPO721997 A AU PO721997A AU PO721997 A0 AUPO721997 A0 AU PO721997A0
Authority
AU
Australia
Prior art keywords
anticancer compounds
anticancer
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPO7219A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
QIMR Berghofer Medical Research Institute
Original Assignee
University of Queensland UQ
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ, Queensland Institute of Medical Research QIMR filed Critical University of Queensland UQ
Priority to AUPO7219A priority Critical patent/AUPO721997A0/en
Publication of AUPO721997A0 publication Critical patent/AUPO721997A0/en
Priority to PCT/AU1998/000431 priority patent/WO1998055449A1/en
Priority to JP50113399A priority patent/JP2002513419A/en
Priority to EP98925331A priority patent/EP0988280A1/en
Priority to AU77516/98A priority patent/AU7751698A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AUPO7219A 1997-06-06 1997-06-06 Anticancer compounds Abandoned AUPO721997A0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AUPO7219A AUPO721997A0 (en) 1997-06-06 1997-06-06 Anticancer compounds
PCT/AU1998/000431 WO1998055449A1 (en) 1997-06-06 1998-06-05 Hydroxamic acid compounds having anticancer and anti-parasitic properties
JP50113399A JP2002513419A (en) 1997-06-06 1998-06-05 Hydroxamic acid compounds with anticancer and antiparasitic properties
EP98925331A EP0988280A1 (en) 1997-06-06 1998-06-05 Hydroxamic acid compounds having anticancer and anti-parasitic properties
AU77516/98A AU7751698A (en) 1997-06-06 1998-06-05 Hydroxamic acid compounds having anticancer and anti-parasitic prop erties

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO7219A AUPO721997A0 (en) 1997-06-06 1997-06-06 Anticancer compounds

Publications (1)

Publication Number Publication Date
AUPO721997A0 true AUPO721997A0 (en) 1997-07-03

Family

ID=3801510

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPO7219A Abandoned AUPO721997A0 (en) 1997-06-06 1997-06-06 Anticancer compounds

Country Status (4)

Country Link
EP (1) EP0988280A1 (en)
JP (1) JP2002513419A (en)
AU (1) AUPO721997A0 (en)
WO (1) WO1998055449A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
KR20010080709A (en) 1998-12-10 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 Procollagen c-proteinase inhibitors
CN1132819C (en) * 1998-12-11 2003-12-31 霍夫曼-拉罗奇有限公司 Cyclic hydrazine derivatives as TNF-alpha inhibitors
WO2000041473A2 (en) * 1999-01-13 2000-07-20 Jomaa Pharmaka Gmbh Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections
AU783504C (en) * 1999-11-23 2006-08-03 Methylgene Inc. Inhibitors of histone deacetylase
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
PE20020354A1 (en) * 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
AU2001290134A1 (en) 2000-09-29 2002-04-08 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
AU2001290131B2 (en) 2000-09-29 2007-11-15 Topotarget Uk Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
AR035659A1 (en) * 2000-12-07 2004-06-23 Hoffmann La Roche HYDROXYAMIDES OF ACID (1-OXO-1,2,3,4-TETRAHIDRO-NAFTALEN-2-IL) -ALCANOICO, PROCESS FOR THE MANUFACTURE OF THESE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND USES OF THE SAME
AR035513A1 (en) * 2000-12-23 2004-06-02 Hoffmann La Roche DERIVATIVES OF TETRAHYDROPIRIDINE, PROCESS TO PREPARE THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USE OF SUCH COMPOUNDS IN THE PREPARATION OF MEDICINES
AR035417A1 (en) 2001-01-27 2004-05-26 Hoffmann La Roche TRICYCLE DERIVATIVES OF LACTAMA AND SULTAMA, PROCESSES FOR THEIR DEVELOPMENT, DRUGS THAT CONTAIN THEM, AND THE USE OF SUCH COMPOUNDS IN THE PREPARATION OF DRUGS
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
AR035455A1 (en) * 2001-04-23 2004-05-26 Hoffmann La Roche TRICYCLE DERIVATIVES OF ALQUILHIDROXAMATO, PROCESSES FOR THEIR DEVELOPMENT, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THE USE OF SUCH COMPOUNDS IN THE PREPARATION OF MEDICINES
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
AR036053A1 (en) 2001-06-15 2004-08-04 Versicor Inc N-FORMIL-HYDROXYLAMINE COMPOUNDS, A PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS
US6784173B2 (en) 2001-06-15 2004-08-31 Hoffmann-La Roche Inc. Aromatic dicarboxylic acid derivatives
DE60219630T2 (en) 2001-06-15 2007-12-27 Vicuron Pharmaceuticals, Inc., Fremont BICYCLIC PYRROLIDIN COMPOUNDS
JP4638148B2 (en) 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ Treatment of neurodegenerative diseases and brain cancer
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040072735A1 (en) 2002-03-04 2004-04-15 Richon Victoria M. Methods of inducing terminal differentiation
ATE458047T1 (en) 2002-03-07 2010-03-15 Univ Delaware METHOD FOR ENHANCING OLIGONUCLEOTIDE-MEDIATED NUCLEIC ACID SEQUENCE CHANGE USING COMPOSITIONS CONTAINING A HYDROXYUREA
AU2003218738B2 (en) 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. Sulfonyl-derivatives as novel inhibitors of histone deacetylase
BR0307624A (en) * 2002-03-13 2005-01-11 Janssen Pharmaceutica Nv Histone Deacetylase Inhibitors
OA12789A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv Carbonylamino-derivatives as novel inhibitors of histone deacetylase.
JP4674045B2 (en) * 2002-03-13 2011-04-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
DK1485354T3 (en) 2002-03-13 2008-09-01 Janssen Pharmaceutica Nv Sulfonylamino derivatives as novel inhibitors of histane deacetylase
AU2003226408B2 (en) * 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
WO2004046104A2 (en) 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
WO2004113336A1 (en) * 2003-06-16 2004-12-29 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
ITMI20041347A1 (en) * 2004-07-05 2004-10-05 Italfarmaco Spa ALPHA-AMINO ACID DERIVATIVES FOR ANTI-INFLAMMATORY ACTIVITIES
NZ552865A (en) 2004-07-28 2009-09-25 Janssen Pharmaceutica Nv Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
EP3354265A1 (en) 2005-03-22 2018-08-01 President and Fellows of Harvard College Treatment of solid tumors
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
JP2009501236A (en) 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド Histone deacetylase inhibitor
US8263044B2 (en) 2005-11-10 2012-09-11 Orchid Research Laboratories Limited Stilbene like compounds as novel HDAC inhibitors
CA2630717C (en) 2006-01-19 2015-02-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
JP5441416B2 (en) * 2006-02-14 2014-03-12 プレジデント アンド フェロウズ オブ ハーバード カレッジ Bifunctional histone deacetylase inhibitor
JP5497431B2 (en) 2006-05-03 2014-05-21 プレジデント アンド フェローズ オブ ハーバード カレッジ Histone deacetylase and tubulin deacetylase inhibitors
CA2702536A1 (en) 2007-10-10 2009-04-16 Orchid Research Laboratories Limited Novel histone deacetylase inhibitors
BRPI0817860A2 (en) 2007-10-22 2019-09-24 Orchid Res Laboratories Limited histone deacetylase inhibitors
AU2009274549B2 (en) 2008-07-23 2014-05-01 Dana-Farber Cancer Institute, Inc. Deacetylase inhibitors and uses thereof
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
KR101735868B1 (en) 2010-02-17 2017-05-15 다케다 야쿠힌 고교 가부시키가이샤 Heterocyclic compound
US20120015942A1 (en) * 2010-07-19 2012-01-19 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US20120015943A1 (en) * 2010-07-19 2012-01-19 Millennium Pharmacuticals, Inc. Substituted hydroxamic acids and uses thereof
US8765773B2 (en) * 2010-10-18 2014-07-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
CN102503857B (en) * 2011-11-02 2014-11-12 沈阳药科大学 Bexarotene hydroximic acid as well as preparation method and application thereof
CR20170420A (en) 2015-03-13 2017-10-03 Forma Therapeutics Inc ALFA-CINAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
WO2020070239A1 (en) 2018-10-04 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115197102B (en) * 2021-04-12 2023-10-20 山东大学 Peptide-like hydroxamic acid plasmodium falciparum aminopeptidase inhibitor, and preparation method and application thereof
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448730A (en) * 1981-03-24 1984-05-15 Riet Bartholomeus Van T Hydroxybenzohydroxamic acids, benzamides and esters and related compounds as ribonucleotide reductase inhibitors
JPS5946244A (en) * 1982-09-09 1984-03-15 Nissan Chem Ind Ltd Hydroxamic acid derivative and its preparation
JPS61176523A (en) * 1985-01-30 1986-08-08 Teruhiko Beppu Carcinostatic agent
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
JP3342485B2 (en) * 1991-12-10 2002-11-11 塩野義製薬株式会社 Aromatic sulfonamide hydroxamic acid derivatives
EP0639982A1 (en) * 1992-05-01 1995-03-01 British Biotech Pharmaceuticals Limited Use of mmp inhibitors
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
JPH07196598A (en) * 1993-12-28 1995-08-01 Kuraray Co Ltd Hydroxamic acid derivative and medicine composition containing the same as active ingredient
DE69529100T2 (en) * 1994-01-22 2003-07-17 British Biotech Pharm metalloproteinase
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
WO1997015553A1 (en) * 1995-10-23 1997-05-01 Sankyo Company, Limited Hyroxamic acid derivatives
JP4358908B2 (en) * 1996-01-02 2009-11-04 アヴェンティス ファーマシューティカルズ インコーポレイテッド Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
AU1812197A (en) * 1996-03-01 1997-09-16 Sankyo Company Limited Hydroxamic acid derivatives
AU2645497A (en) * 1996-05-06 1997-11-26 Zeneca Limited Thio derivatives of hydroxamic acids
GB9609794D0 (en) * 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
GB9609795D0 (en) * 1996-05-10 1996-07-17 Smithkline Beecham Plc Novel compounds
CA2263154A1 (en) * 1996-08-07 1998-02-12 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
IL128189A0 (en) * 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives

Also Published As

Publication number Publication date
JP2002513419A (en) 2002-05-08
WO1998055449A1 (en) 1998-12-10
EP0988280A1 (en) 2000-03-29

Similar Documents

Publication Publication Date Title
AUPO721997A0 (en) Anticancer compounds
AU1709299A (en) Mixer-injectors
AU8921698A (en) Follistatin-3
AU6364598A (en) Chromene compound
AU7210598A (en) Novel compounds
AU6598798A (en) Resorcinyl-triazines
AU6804098A (en) Triazinylaminostilbene compounds
AU1027499A (en) 32P-polyphosphazene
AU3645397A (en) Anticancer agents
AU8591898A (en) Pharmaceutical compounds
AU6827898A (en) Detergent-package combination
AU5272198A (en) EMP-charge-eliminator
AU7476598A (en) 18-substituted-19-nor-vitamin d compounds
AUPO941497A0 (en) Novel compounds
AU4117497A (en) Micropolarimeter
AU6998698A (en) Dioxacycloalkan-8-one
AUPP042397A0 (en) 5-arylpyrazole compounds
AU7124598A (en) Polymer-platinum compounds
AU6185898A (en) Clavaspirins
AU7761998A (en) Korrosionsschutzanstrichstoff
AU8214598A (en) 3-benzylpiperidine
AU8019998A (en) Fluoromethoximino compounds
AU7041098A (en) Pi-complex compounds
AU9753998A (en) Azaboroxine compounds
AU4469997A (en) Heregulin-gamma